Clinical Trial

Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis

Study acronym: PTX-PSO
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study will evaluate whether pentoxifylline, when used as an add-on treatment to standard topical therapy, is effective and safe for adults with mild-to-moderate plaque psoriasis. Participants will be randomly assigned to receive either pentoxifylline or placebo twice daily for 12 weeks, while continuing their standard topical treatment. The study will compare improvement in psoriasis severity, itch, physician assessment, quality of life, and adverse events between the two groups. Participants will be followed for a total of 16 weeks.
Trial Details
NCT Number NCT07626788
Lead Sponsor Wasuchon Chaichan
Conditions Psoriasis
Enrollment 140 participants
Start Date 2026-06-15
Primary Completion 2027-03 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-05